MARKET

BIOC

BIOC

Biocept Inc
NASDAQ
0.6752
+0.0002
+0.03%
Closed 17:28 12/08 EST
OPEN
0.6750
PREV CLOSE
0.6750
HIGH
0.7000
LOW
0.6750
VOLUME
82.19K
TURNOVER
--
52 WEEK HIGH
4.250
52 WEEK LOW
0.6700
MARKET CAP
11.52M
P/E (TTM)
-1.0361
1D
5D
1M
3M
1Y
5Y
Biocept Q3 EPS $(0.33) Down From $(0.04) YoY, Sales $5.59M Down From $17.47M YoY
Benzinga · 11/21 21:10
BRIEF-Biocept Reports Third Quarter 2022 Financial Results
Reuters · 11/21 21:08
Biocept Q3 Loss Widens, Revenue Drops
Biocept Q3 Loss Widens, Revenue Drops
MT Newswires · 11/21 16:57
-- Earnings Flash (BIOC) BIOCEPT Posts Q3 Revenue $5.6M
-- Earnings Flash (BIOC) BIOCEPT Posts Q3 Revenue $5.6M
MT Newswires · 11/21 16:11
BRIEF-Biocept Appoints Financial Executive Quyen Dao-Haddock To Its Board Of Directors
Reuters · 11/18 13:06
Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors
SAN DIEGO, November 18, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of Quyen Dao-Haddock to its Board of Directors, effective immediately, increasing Board membersh...
Business Wire · 11/18 13:00
Biocept Announces Participation In An Investigator-Initiated Study To Better Understand The Development And Progression Of Metastatic Breast Cancer To The Central Nervous System
Benzinga · 11/16 13:10
Biocept GAAP EPS of -$0.31, revenue of $10.6M
Seekingalpha · 11/10 22:01
More
About BIOC
Biocept, Inc. is a molecular oncology diagnostics company. The Company focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify tumor cells and cell-free tumor deoxyribonucleic acid (DNA) from blood, and cerebrospinal fluid (CSF). Its product is branded and trademarked under the name of CNSide. In addition to CNSide, its current blood-based testing includes its Target Selector technologies, which enables detection of specific gene mutations, such as EGFR, KRAS or BRAF, in cell-free ctDNA from blood samples, as well as specific protein and gene alterations, such as HER2 amplification, in circulating tumor cells (CTCs) isolated from blood. Its multi-modality combination of a cell capture and analysis method used with a cell-free tumor DNA approach provides both high-sensitivity and specificity and is applicable to a range of diagnostic applications in patients with metastatic carcinoma. It provides blood-based liquid biopsy technology.

Webull offers kinds of Biocept Inc stock information, including NASDAQ:BIOC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIOC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BIOC stock methods without spending real money on the virtual paper trading platform.